Professor Heather Payne is a Consultant Clinical Oncologist, specialising in urological and prostate cancer at University College London Hospitals NHS Trust and she also sees patients privately, including at The Harley Street Clinic and The Prostate Centre.

Professor Payne trained at St Mary’s Hospital and after qualifying, spent time in general medicine in London and Haiti.

On her returned to London, she trained as a Clinical Oncologist, and also developed an interest in urological oncology.

In addition to her clinical work, she is also actively involved in research, and she has pioneered a program of high-dose rate brachytherapy for prostate cancer. Current research interests include hormone therapy, sensitisation of hormones and radiotherapy, predictive indices for bowel toxicity with radiotherapy, proton beam therapy for prostate cancer, chemotherapy and assisting men with decision making and prostate cancer.

Professor Payne is principal investigator in a number of international and national studies and has been published in peer-reviewed journals. She is Chair of the British Uro-oncology Group and Oncology Lead for the National Prostate Cancer Audit. She also serves on the Prostate Cancer Advisory Group for the UK.

• External Beam Radiotherapy
• Intensity Modulated Radiotherapy/Rapid Arc
• Low Does Brachytherapy
• Hormone Treatment

• Prostate Cancer
• Novel Hormone Therapy
• External beam radiotherapy
• Chemotherapy
• Brachytherapy
• 
  

Dr Mary McCormack is a Consultant Clinical Oncologist, specialising in gynaecological andf breast cancers. She qualified in medicine from Guy's and St Thomas' Hospital. Before medical school, she undertook research in radiation biology and was awarded a PhD in 1989. Dr McCormack has worked in leading London cancer centres and in 2000, she was awarded the FRCR in clinical oncology. She was appointed a consultant at University College London Hospital in 2002.

Dr McCormack treats all subtypes of gynaecological cancer, including ovary, womb, uterus, cervix, vulva, vagina and also treats breast cancer. Treatments include chemotherapy, targeted/ biological therapy,radiotherapy and brachytherapy. She has a particular interest in cervical cancer treatment and targeted agents in breast, ovarian and endometrial cancer. Dr McCormack is a major contributor to national and international clinical trials and is the chief investigator on a nuber of studies. She is the current chair of the international Cervical Cancer Research Network (CCRN)and an exective member of the Gynaecologic Cancer Intergroup (GCIG)and a member of the International Gynaecologic Cancer Society's education committee.She is also a member of the ASCO International Affairs Committee.

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

• Radiotherapy
• Chemotherapy
• Brachytherapy

• Cervical Cancer
• Breast Cancer
• Gynaecological Cancers
• uterine cancer
• vaginal and vulval cancer
• ovary cancer
• chemotherapy 
• biological therapy
• radiotherapy

Dr Mulholland is a medical Oncologist who exclusively treats brain cancer at University College Hospital, the National Hospital for Neurology and Neurosurgery (part of UCLH) and Mount Vernon Cancer Centre.He is also an honorary senior lecturer at UCL and a training programme director. 

His doctoral research was in genomic profiling in brain cancer at Cancer Research UK - this has led to his focus on developing biomarkers and targets for therapy in brain cancer, including the clinical trial portfolio of novel agents in brain cancer which he now runs at UCLH and nationally. 

He is a clinical lead in a European Consortium called Datrix, a multidisciplinary European collaboration to advance next-generation targeted hyperthermic cancer treatment for glioblastoma.

Diseases, Medical Tests and Treatments

• Cancer prevention and screening 
• Chemotherapy 
• Brain cancer 
• Neuro-endocrine tumours 
• Central nervous system cancer 
• Novel agents 

Dr Sarah Harris has been a Consultant Clinical Oncologist working at Guy’s and St Thomas’ NHS Trust for over 20 years. She now only sees patients privately at a range of private centres across London as well as by remote video consultation . Her areas of interests include breast cancer, prostate cancer and urological cancer, and she treats these conditions using radiotherapy and chemotherapy in central London and the south east of England.

She has extensive clinical experience in the management of breast cancer using radiotherapy and drug treatments. She has a specialist interest in technical radiotherapy due to its maximal benefits and reduced side effects. In particular she uses heart sparing radiotherapy techniques for left-sided breast radiotherapy. Furthermore, she regularly uses stereotactic radiotherapy for the treatment of localised recurrent cancers using the latest radiotherapy technologies, cyberknife and SABR. For the treatment of prostate cancer, she can perform external radiotherapy using modern IMRT and IGRT.

Along with her wealth of experience, she completed specialist training in proton beam radiotherapy at the University Of Pennsylvania in 2020. Dr Harris also holds many professional memberships, including the Royal College of Physicians and the Royal College of Radiologists.

In her leisure time , she is a keen golfer aspiring to a single figure handicap.

• Radiotherapy
• Chemotherapy
• CyberKnife therapy
• Stereotactic Ablative Radiotherapy (SABR)
• Proton beam radiotherapy

• Breast Cancer
• Prostate Cancer
• Urological Cancers

Dr Amen Sibtain is a Consultant Clinical Oncologist specialising in the management of Gastrointestinal, Hepatobiliary and Head and Neck cancers with chemotherapy and radiotherapy. He is also highly experienced in chemo-radiotherapy, state of the art radiotherapy techniques, including VMAT, stereotactic radiotherapy and radiosurgery, and intraoperative radiotherapy.

Dr Sibtain is presently the Clinical Director of GI oncology and Radiotherapy at St Bartholomew’s Hospital, an examiner in oncology for the Royal College of Radiologists, a member of the medical advisory panel for both Macmillan and CRUK, oncology advisor for BBC Drama and the Clinical Lead in Head and Neck Cancer at Barts. Dr Sibtain was previously President of the Oncology Section of the Royal Society of Medicine, Programme Director for Clinical Oncology Specialist Training Committee for the London Deanery and Chairman of the Head and Neck Tumour Board for North East London. He also previously worked at the Royal Marsden, Mount Vernon and The Middlesex Hospitals, before he took up his post at Barts. He was awarded an MD degree for his research in tumour hypoxia by the University of London.

As well as his clinical work he remains actively involved in research. He has been published in a number of peer-reviewed journals and edited the books Towards the Prevention of Cancer (2007) and Physics for Clinical Oncologists (2012).

Diseases, Medical Tests and Treatments

• Chemotherapy
• Cyberknife Therapy
• Intensity Modulated Radiotherapy 
• Radio Surgery
• Radiotherapy
• Rapid Arc
• Stereotactic Radiotherapy 
• Volumetric Arc Radiotherapy 
• Anal Cancer
• Bilary Cancer
• Bowel Cancer  
• Colon Cancer
• Gastro-Intestinal Cancers
• Head & Neck Cancers
• Liver Cancer
• Oesophageal Cancer
• Pancreatic Cancer
• Rectal Cancer
• Stomach Cancer

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

Dr. John Conibear completed his initial medical training at the University Hospital of Wales in 2001 and completed his post-graduate general medical training in The Barts and The London Training rotation in 2006. Before gaining his substantive post as a consultant clinical oncologist in St. Bartholomew’s Hospital in 2014, he completed a 2-year fellowship with the NCRI Radiotherapy Trials Quality Assurance Group in Mount Vernon Hospital. During his fellowship, he conducted research into techniques to improve clinician target outlining during radiotherapy planning and was subsequently awarded an MD(Res) from UCL in 2018.

Dr. Conibear is currently deputy medical director and deputy director of Barts Cancer Centre. Dr Conibear specialises in all the non-surgical treatments for both lung and breast cancers. He has expertise in chemotherapy, biological therapy, immunotherapy, radiotherapy and state of the art radiotherapy techniques including deep inspiration breath-hold (DIBH) for early breast cancer, Intensity Modulated Radiotherapy (IMRT), Image-Guided Radiotherapy (IGRT), 4D-CT and both Cyberknife and Gamma Knife (stereotactic radiotherapy). He is also currently the lead for chemotherapy and clinical director for thoracic oncology in St. Bartholomew’s Hospital in addition to his private practice.

• Chemotherapy
• Deep Inspiration Breath Hold
• Gamma Knife
• Image-guided radiotherapy (IGRT)
• Immunotherapy
• Intensity modulated radiotherapy (IMRT)
• Radiotherapy

• Breast cancer
• Lung cancer

Dr Jonathan Krell is a Consultant Oncologist specialising in breast and gynaecological cancers, with particular interest in cancer genetics and hereditary malignancies, especially with respect of BRCA and other gene mutations. His clinical focus is on the systemic management of patients with gynaecological and breast cancers. 

Dr Krell qualified in medicine at Leeds University Medical School, where he also gained a first class honours degree in Pharmacology. He completed junior doctor positions at St James’ Hospital, Leeds and St Thomas’ Hospitals in London. He then undertook oncology training at Charing Cross and Hammersmith Hospitals.

His PhD work was funded by the Medical Research Council and this investigated the interplay between genetic mutations, DNA damage and the response to cancer therapeutics. Dr Krell is a leading member of the translational research team within the Cancer Research UK and Ovarian Cancer Action centres at Imperial College that aim to overcome resistance to current anti-cancer agents in ovarian and breast cancer.

Dr Krell has published more than 100 peer-reviewed papers in academic journals and he regularly presents on his research at national and international conferences.

• Chemotherapy
• Radiotherapy
• Genetic Testing

• Breast Cancer
• Ovarian Cancer
• Gynaecological Cancers

Dr Susan Cleator is a Consultant Clinical Oncologist with extensive experience in breast, colorectal and lymphomatous cancers. She has a specialist interest in early breast cancer and treatment of breast cancer in young women.

After studying medicine at Oxford University and Hospitals, she completed her specialist oncology training at the Charing Cross, Hammersmith, Mount Vernon and The Royal Marsden Hospitals. During this time she spent three years working on her PhD project at the Institute of Cancer Research and Royal Marsden Hospital. Her research focused on identifying a molecular assay for predicting the response of breast cancers to chemotherapy.

Dr Cleator works closely with a multi-disciplinary team at St Mary’s hospital where she is responsible for the chemotherapy and radiotherapy aspect of the patient’s treatment. She is actively involved in research into both breast and colorectal cancers, and has been published in a number of peer-reviewed journals. She is also a member of a number of research groups including the National Cancer Research Institute (NCRI) Breast Cancer Studies Group (BCSG).

• Chemotherapy 
• Radiotherapy 

• Breast Cancer 
• Gastro-intestinal cancers 

Professor Andrew Tutt is a Consultant Clinical Oncologist specialising in breast cancer. He is based at Guy’s Hospital Breast Unit but also performs private work and is a Professor of Oncology at King’s College London School of Medicine.

He qualified in medicine in 1990 and went on to complete his postgraduate training at a number of hospitals around the UK. After completing his clinical oncology training at the Royal Marsden Hospital London, he was awarded a Doctoral Research Training Fellowship at The Institute of Cancer Research, London, where he gained his PhD in cancer biology.

Professor Tutt is actively involved in clinical research and has published a number of breast cancer research papers. His main areas of research include the ‘triple negative’ and BRCA1 and BRCA2 associated breast cancers. He has led a number of international trials of drug therapies and research programmes in these areas.

He is often asked to speak at major European and North American Cancer Medicine conferences. He is a member of the St Gallen International Breast Cancer Consensus Panel that develops guidelines for the treatment of breast cancer. He is also part of a UK team that trial new techniques in breast radiotherapy.

• Biological Therapy 
• Chemotherapy 
• Radiotherapy 

• Breast Cancer 

Dr Beatrice Seddon is consultant on the Sarcoma Unit at University College Hospital, which together with the Bone Tumour Unit at the Royal National Orthopaedic Hospital, comprises the London Bone and Soft Tissue Tumour Service.

Dr Seddon trained in treating sarcomas at the Royal Marsden and Middlesex Hospitals in London, and now specialises exclusively in the treatment of soft tissue and bone sarcomas with chemotherapy and radiotherapy.

She completed her PhD (University of London) at the Institute of Cancer Research in imaging of tumour hypoxia, and currently has a strong interest in clinical trials in sarcoma, acting as principal and chief investigator for a number of national and international trials. She is actively involved in coordinating sarcoma research at a national level as a member of the NCRN Sarcoma Clinical Studies Group, and is also a member of the EORTC Soft Tissue and Bone Sarcoma Group. She regularly teaches and lectures on the management of sarcomas.

• Chemotherapy
• Radiotherapy

• Bone Cancer
• Sarcoma